⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2025

Supplemental Figure 4 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer

Rosa A. van Amerongen Sander Tuit Dennis F.G. Remst Anne K. Wouters Sterre L. Siekman Renate S. Hagedoorn Dirk M. van der Steen Michel G.D. Kester Arnoud H. de Ru Geertje van der Horst Masashi Matsuda Fumihiko Ishikawa Peter A. van Veelen J.H. Frederik Falkenburg Mirjam H.M. Heemskerk

View at Publisher

Ask AI

Bookmark

Share

Key Points

MAIN FINDING: TCR-based therapy targeting kallikrein-related peptidase 4 is safe and effective against prostate cancer.
KEY EVIDENCE: T-cell clones produced IFN-ƴ when cocultured with Raji cells loaded with specific peptides.
APPROACH: T-cell clones were selected based on their ability to recognize peptide-loaded Raji cells with varying peptide concentrations.
SIGNIFICANCE: This research supports immunotherapy as a viable treatment option for prostate cancer, enhancing therapeutic strategies.

Implication

TCR-based therapy shows safety and effectiveness against prostate cancer, revealing the role of T-cell clones and peptide interactions.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Amerongen et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d030e https://doi.org/10.1158/2326-6066.29759684

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Figure 6 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer2025
2Supplemental Figure 7 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer2025
3Supplemental Figure 5 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer2025
4Supplemental Figure 3 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer2025
5Data from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer2025

Supplemental Figure 1 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer2025
Supplemental Figure 8 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer2025
Supplemental Figure 2 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer2025